All In MedTech

Device Trial Radar · NCT03983707

A Evaluation of the Utilisation, Effectiveness and Safety of Purastat® in the Management of Gastrointestinal Bleeding

A Multicentre Prospective Observational Study to Evaluate the Utilisation, Effectiveness and Safety of Purastat® in the Management of Gastrointestinal Bleeding

Last checked: Nov 19, 2026Latest source record: May 31, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

379

Actual

Start

Jan 23, 2019

Primary completion

Oct 31, 2021

Study completion Oct 31, 2021

Sponsor

Lead sponsor
Portsmouth Hospitals NHS TrustGovernment (non-federal)
Sponsor type
Government (non-federal)
Collaborators
3-D Matrix Europe SAS; Gloucestershire Hospitals NHS Foundation Trust; Cambridge University Hospitals NHS Foundation Trust; University Hospital Birmingham NHS Foundation Trust; Nottingham University Hospitals NHS Trust; Mid and South Essex NHS Foundation Trust; East Kent Hospitals University NHS Foundation Trust; University College London Hospitals; North Tees and Hartlepool NHS Foundation Trust; Brighton and Sussex University Hospitals NHS Trust; King's College Hospital NHS Trust; Imperial College Healthcare NHS Trust; Heart of England NHS Foundation Trust; The Leeds Teaching Hospitals NHS Trust; Barts & The London NHS Trust; London North West Healthcare NHS Trust; Manchester University NHS Foundation Trust; Oxford University Hospitals NHS Trust; Glasgow Royal Infirmary; Guy's and St Thomas' NHS Foundation Trust; Northern Care Alliance NHS Foundation Trust; University Hospital Southampton NHS Foundation Trust
First posted
Jun 12, 2019

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
No
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Problem statement GI bleeding can arise from peptic ulcers, malignancy, angiodysplasia or during endoscopic resection procedures such as endoscopic mucosal resection and endoscopic submucosal dissection. This is conventionally treated using heat therapy or clips. These methods carry a risk of thermal injury or perforation. Purastat® is a novel synthetic haemostatic agent licensed as a CE marked device for use in GI bleeding. It also has the potential to enhance endoscopic mucosal wound healing and may play a role in preventing delayed bleeding. However, clinical data on its effectiveness in the GI tract is limited. Prospective data collection on the range of indications for Purastat® use and outcome data related to clinical effectiveness, safety and feasibility is required to inform clinicians about the best use for this agent. Research question / hypothesis To establish a prospective registry study to collect outcome data related to the use of Purastat® for the clinical management of GI bleeding or prevention of bleeding Study Design Prospective multicentre cohort study Study Participants Adults with GI bleeding or a high risk of bleeding during endoscopic procedures where Purastat® has been used Follow-up duration All patients will be followed up as per standard clinical care where applicable Planned Study Period 2 years Primary Objective To assess the effectiveness of Purastat® as a haemostatic agent when used in the treatment of GI bleeding Secondary Objectives To assess the incidence of delayed bleeding after use of Purastat®, defined as procedure related bleeding up to 28 days following endoscopic resection To evaluate the rate of rebleeding following primary application of Purastat® for haemostasis To assess the technical feasibility and ease of use of Purastat® when used in the treatment or prevention of GI bleeding To monitor any unexpected reactions that may be attributed to the use of Purastat® To describe utilisation patterns in different clinical centres (indication, patient characteristics etc) and to observe trends in utilisation over time

Conditions

  • Gastrointestinal Bleeding
  • Delayed Bleeding

Interventions

  • Purastat®Device

    Use of Purastat®

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Effectiveness of Purastat® in controlling bleedingTime frame: Day 1 (intraprocedural bleeding)
  2. Effectiveness of Purastat® in controlling bleedingTime frame: Day 28 (delayed bleeding)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Queen Alexandra Hospital

    Portsmouth, Hampshire, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.